Repros to Present at Biocentury's NewsMakers in the Biotech Industry Conference
September 23, 2013 10:40 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski, President and CEO of Repros Therapeutics, will be...
Repros Provides Additional Information Confirming Success for Study ZA-302
September 18, 2013 10:27 ET
|
Repros Therapeutics Inc.
SPA Co-Primary Endpoints Met
Results In Line with Study ZA-301 Findings
All Studies Fully Compliant with FDA Good Clinical Practice
THE WOODLANDS, Texas, Sept. 18, 2013 (GLOBE NEWSWIRE) --...
Repros Reports Preliminary Findings: Second Pivotal Study and 6-Month Safety Study Support Androxal(R) Approvability
September 16, 2013 20:01 ET
|
Repros Therapeutics Inc.
Androxal meets both co-primary endpoints in second pivotal study ZA-302
Testosterone normalized in 81% of patients
No deleterious effects on sperm function
No excursions...
Repros Reports 6 Month Bone Mineral Density Data From Ongoing Study ZA-303
August 20, 2013 16:01 ET
|
Repros Therapeutics Inc.
No bone loss compared to placebo
Early evidence of improving bone mineral density in Androxal® subjects
THE WOODLANDS, Texas, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics...
Repros Therapeutics Inc.(R) Reports Second Quarter 2013 Financial Results
August 07, 2013 09:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2013.
Liquidity and...
Repros Seeks to Affirm Its Intellectual Property Rights in Androxal(R)
August 05, 2013 09:00 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has filed an action in the United States District Court for the Southern District...
Repros Announces Formation of Androxal(R) Clinical and Commercial Advisory Board
July 09, 2013 13:15 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, July 9, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the formation of an international, multi-disciplinary, clinical advisory board to...
Repros Therapeutics Inc.(R) Announces the Closing of Public Offering of Common Stock
June 25, 2013 11:47 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, June 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has closed an underwritten public offering of 4,312,500 shares of its common...
Repros Therapeutics Inc.(R) Announces Pricing of Public Offering of Common Stock
June 19, 2013 19:35 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, June 19, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at...
Repros Therapeutics Inc.(R) Announces Proposed Public Offering of Common Stock
June 17, 2013 16:01 ET
|
Repros Therapeutics Inc.
THE WOODLANDS, Texas, June 17, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has commenced an underwritten public offering of up to 3,000,000 shares of its...